- Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective studyWang, Kun; Huang, YuhongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer (vol 308, e222830, 2023)Shi, Zhenwei*; Huang, Xiaomei; Cheng, Ziliang; Xu, Zeyan; Lin, Huan; Liu, Chen; Chen, Xiaobo; Liu, Chunling; Liang, Changhong; Lu, Cheng; Cui, Yanfen; Han, Chu; Qu, Jinrong; Shen, Jun; Li, ZaiyiRADIOLOGY, 2023, 308(1): e239021.
- Prognostic value of the tumor-infiltrating lymphocytes in Miller-Payne grade 4 triple-negative breast cancer following neoadjuvant chemotherapyMa, Jianli; Deng, Yuwei; Chen, Dawei; Li, Xiaomei; Yu, Zhiyong; Wang, Haibo; Zhong, Lei; Li, Yingjie; Wang, Chengqin; Zhou, Xiaoping; Li, Xiang; Zhang, Qingyuan; Yu, JinmingAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
会议论文
Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized, prospective cohort study.
8阅读
